The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into Phase I trials, with additional preclinical assets targeting Parkinson’s and ...

Researchers have succeeded in creating a close connection between individual cells and organic electronics. The study lays the foundation for future treatment of neurological and other diseases with ...

One fateful morning, 75-year-old Ambika Devi suddenly felt the room around her spinning, reminiscent of an amusement park ...

A remote camera set up to monitor a neurological disorder in wild cats has captured something unexpected—footage of a bobcat ...

Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...

Maharashtra Health Minister Prakash Abitkar confirmed on Monday that Pune has recorded 111 cases of Guillain-Barre Syndrome (GBS) to date.

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder where the immune system attacks peripheral nerves, causing ...

The Clinic's study has already enrolled 3,600 participants, but the goal is a diverse group of 200,000. Right now, more men ...

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed ...

A PIECE of artwork designed to help people with neurological conditions has left locals inspired at Barnsley Hospital.In...

In this webinar, Ed Boyden and Jerzy Szablowski will talk about how synthetic biology can help develop tools for studying and ...